SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed as novel targeted agents in gastric cancer. Here, we sought to evaluate the efficacy of ATRi...

Descripción completa

Detalles Bibliográficos
Autores principales: Llorca-Cardenosa, Marta J., Aronson, Lauren I., Krastev, Dragomir B., Nieminuszczy, Jadwiga, Alexander, John, Song, Feifei, Dylewska, Malgorzata, Broderick, Ronan, Brough, Rachel, Zimmermann, Astrid, Zenke, Frank T., Gurel, Bora, Riisnaes, Ruth, Ferreira, Ana, Roumeliotis, Theodoros, Choudhary, Jyoti, Pettitt, Stephen J., de Bono, Johann, Cervantes, Andres, Haider, Syed, Niedzwiedz, Wojciech, Lord, Christopher J., Chong, Irene Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Molecular Cell Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627126/
https://www.ncbi.nlm.nih.gov/pubmed/36273494
http://dx.doi.org/10.1158/0008-5472.CAN-21-4339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627126/
https://www.ncbi.nlm.nih.gov/pubmed/36273494
http://dx.doi.org/10.1158/0008-5472.CAN-21-4339

Ejemplares similares